Wedbush analyst, David Nierengarten, doubts bidders will appear for Raptor Pharmaceuticals (NASDAQ: RPTP) due to the slow growth and limited ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE